Beaumont Hospital, RCSI Cancer Centre, D09 V2N0 Dublin, Ireland.
Department of Medicine, RCSI University of Medicine and Health Sciences, D02 YN77 Dublin, Ireland.
Curr Oncol. 2023 Jul 20;30(7):6862-6871. doi: 10.3390/curroncol30070502.
Immune checkpoint inhibitors (ICIs) are a class of drug that produces durable and sustained anti-tumour responses in a wide variety of malignancies. The exponential rise in their use has been mirrored by a rise in immune-related adverse events (IrAEs). Knowledge of such toxicities, as well as effective management algorithms for these toxicities, is essential to optimize clinical efficacy and safety. Currently, the guidelines for management of the IrAEs are based largely on retrospective studies and case series. In this article, we review the current landscape of clinical trials investigating the management of IrAEs with an aim to develop standardised, randomised controlled trial-based management algorithms for ICI-related toxicities.
免疫检查点抑制剂（ICIs）是一类药物，可在多种恶性肿瘤中产生持久和持续的抗肿瘤反应。随着其应用的迅速增加，免疫相关不良事件（IrAEs）也随之增加。了解这些毒性以及针对这些毒性的有效管理算法对于优化临床疗效和安全性至关重要。目前，IrAEs 管理指南主要基于回顾性研究和病例系列。在本文中，我们回顾了目前正在进行的临床试验，以研究 IrAEs 的管理，旨在为 ICI 相关毒性制定标准化、基于随机对照试验的管理算法。
